Patents by Inventor Ladislav J. Hanka

Ladislav J. Hanka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biologically pure culture of Paecilomyces abruptus
    Patent number: 4282327
    Abstract: New antibiotic U-53,946 produced by the controlled fermentation of the new microorganism Paecilomyces abruptus sp. nov., NRRL 11110. This antibiotic is active against Gram-positive bacteria, for example, Sarcina lutea, Staphylococcus aureus, Bacillus subtilis, Mycobacterium avium, and Streptococcus pyogenes, and the yeast Saccharomyces pastorianus. Accordingly, they can be used in various environments to eradicate or control these microorganisms.
    Type: Grant
    Filed: June 21, 1978
    Date of Patent: August 4, 1981
    Assignee: The Upjohn Company
    Inventors: Ladislav J. Hanka, Paul F. Wiley
  • Composition of matter and process
    Patent number: 4169888
    Abstract: Novel antibiotic CC-1065 producible in a fermentation under controlled conditions using the new microorganism Streptomyces zelensis, NRRL 11,183. This antibiotic is active against Gram-positive bacteria, for example, Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes, Sarcina lutea, and Streptococcus faecalis. It is also active against Gram-negative bacteria, for example, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Salmonella pullorum. Thus, antibiotic CC-1065 can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: October 17, 1977
    Date of Patent: October 2, 1979
    Assignee: The Upjohn Company
    Inventors: Ladislav J. Hanka, David G. Martin
  • Antibiotic U-53,946 and process for preparing the same
    Patent number: 4123521
    Abstract: New antiobiotic U-53,946 produced by the controlled fermentation of the new microorganism Paecilomyces abruptus sp. nov., NRRL 11110. This antibiotic is active against Gram-positive bacteria, for example, Sarcina lutea, Staphylococcus aureus, Bacillus subtilis, Mycobacterium avium, and Streptococcus pyrogenes, and the yeast Saccharomyces pastorianus. Accordingly, they can be used in various environments to eradicate or control these microorganisms.
    Type: Grant
    Filed: April 22, 1977
    Date of Patent: October 31, 1978
    Assignee: The Upjohn Company
    Inventors: Ladislav J. Hanka, Paul F. Wiley
  • Antibiotic U-43,120 and process for preparing same
    Patent number: 3988441
    Abstract: New antibiotic U-43,120 producible by the controlled fermentation of the new microorganism Streptomyces paulus, NRRL 8115.This antibiotic is active against Gram-positive and Gram-negative bacteria. Accordingly, it can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: October 2, 1975
    Date of Patent: October 26, 1976
    Assignee: The Upjohn Company
    Inventors: Ladislav J. Hanka, Paul F. Wiley
  • .alpha.S, 4S, 5R .alpha.-Amino-3-chloro-4-hydroxy-2-isoxazoline-5-acetic acid
    Patent number: 3944562
    Abstract: Antibiotic U-43,795, producible by culturing Streptomyces sviceus in an aqueous nutrient medium has the following structure ##EQU1## The absolute configuration of U-43,795 was determined to be .alpha.S, 4S, 5R .alpha.-amino-3-chloro-4-hydroxy-2-isoxazoline-5-acetic acid. It is an amphoteric compound and can exist in different ionic forms according to the pH of the environment. At low pH, U-43,795 exists in the acid-addition salt form, at a higher pH in a zwitterion form, and at still higher pH in a metal salt form. U-43,795 inhibits the growth of Bacillus subtilis and Sarcina lutea, and can be used to inhibit such microorganisms in various environments.
    Type: Grant
    Filed: April 17, 1974
    Date of Patent: March 16, 1976
    Assignee: The Upjohn Company
    Inventors: David G. Martin, Ladislav J. Hanka